Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) ...

The global CRISPR gene editing market size is calculated at USD 4.77 billion in 2025 and is expected to reach around USD ...

A man who was the first person in the UK to receive a groundbreaking gene-editing therapy on the NHS, said he felt " ...

Between Casgevy's long-term potential and the company's innovative pipeline, CRISPR Therapeutics could eventually recover and ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

While Casgevy is the first-ever approved CRISPR/Cas9 gene-edited therapy, its initial commercial uptake has been modest. Despite the groundbreaking nature of the therapy, Vertex recorded just $10 ...

CRSP’s Competition for Casgevy While Casgevy is currently the only CRISPR-based therapy, several companies are advancing gene-editing treatments using similar technology.

Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large markets. Click for my CRSP update.

CRISPR is revolutionizing medicine by enabling precise DNA edits, treating genetic diseases like sickle cell anemia and ...